ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements with these filters
Q2FY27 operating revenue ₹230.23 Cr, operating EBITDA ₹42.33 Cr (18.02% margin), PAT ₹31.03 Cr (13.21%) after API exit; now net debt-free FDF pure-play.
Ind-Swift Laboratories Limited submitted its quarterly monitoring agency report for the period ended September 30, 2026. The report covers the utilization of Rs. 137.20 Crore raised via warrants.
Ind-Swift Laboratories has fully utilized the Rs. 314.60 Crore proceeds from its preferential issue of convertible warrants. The monitoring agency CARE Ratings confirms no deviations in fund usage.
Ind-Swift Laboratories reported Q2 FY27 revenue up 50% to ₹234.89 crore and PAT up 3.5x to ₹31.03 crore. Operating EBITDA margin rose to 18.02%.
Ind-Swift Laboratories Ltd reported revenue from operations of ₹240.5 Cr (+51.6% YoY) and net profit of ₹34.2 Cr (+327.5% YoY) for Q2 FY27.
Ind-Swift Laboratories Ltd. scheduled a board meeting for October 29, 2026, to consider and approve the standalone and consolidated financial results for the quarter and half-year.
Essix Biosciences Limited acquired 14,00,000 equity shares of Ind-Swift Laboratories Limited following the conversion of fully convertible warrants. The company disclosed this under SEBI regulations.
Ind-Swift Laboratories allotted 14,00,000 equity shares upon conversion of warrants at Rs. 196 each. The allotment follows a previously approved preferential issue.
Ind-Swift Laboratories allotted 14 lakh equity shares upon converting warrants for Essix Biosciences Limited, receiving ₹20.58 Crore. This increases the company's paid-up equity share capital.
Ind-Swift Laboratories Limited held its 31st Annual General Meeting on September 30, 2026. Members approved audited financial statements and director appointments.
KMP Pardeep Verma sold 6,140 equity shares of Ind-Swift Laboratories Ltd via market sale, reducing his holding by 0.01%.
Ind-Swift Laboratories Ltd has filed its quarterly shareholding pattern as mandated by Regulation 31(1)(c) of the SEBI Listing Regulations.
Promoter entity Essix Biosciences Limited acquired 70,00,000 fully convertible warrants of Ind-Swift Laboratories via a preferential allotment.
Ind-Swift Laboratories allotted 70 lakh fully convertible warrants at Rs. 196 each, totaling Rs. 137.2 Crore. This preferential issue will augment capital upon warrant conversion.
Ind-Swift Laboratories Limited allotted 70,00,000 fully convertible warrants to Essix Biosciences Limited on a preferential basis. The company received Rs. 34.30 Crore as upfront payment.